Effect of Initiation of Veno-venous ECMO on Urine Output and Acute Kidney Injury (VENTURI)
Effect of Ultraprotective Ventilation After Veno-venous ECMO Initiation on Urine Output and Acute Kidney Injury (VENTURI) - a Retrospective Single Center Study
With this study, the investigators want to find out whether the use of a "lung machine" (extracorporeal membrane oxygenation (ECMO)) togethet with giving the lungs "rest" (by minimizing ventilary support) in people with severe pneumonia has an effect on how well the kidneys work.
The investigators will use information that was already collected while patients were staying in the intensive care unit. Patients do not need to do anything additional or undergo any additional procedures for this study.
Study Overview
Status
Status
Conditions
Conditions
Detailed Description
Some people with severe pneumonia need to be admitted to the intensive care unit. In very serious cases, the lungs may work so poorly that breathing without help is no longer possible. These patients then receive support from a breathing machine (a ventilator). Sometimes even this support is not enough, and a special machine is needed to temporarily take over the function of the lungs. This machine is called a "lung machine" (also known as ECMO).
When a patient is connected to this lung machine, the patient's own lungs are exposed to as little pressure and stimulation as possible. This is called "lung rest" and gives the lungs time to heal.
In people who are very ill, such as those with severe pneumonia, other organs can also be affected. The kidneys, which are important for making urine and removing waste products from the body, may suddenly stop working as well as they should. This study will examine whether using the lung machine and lung rest affects how the kidneys work.
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Ghent, Belgium, 9000
- Ghent University Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Age 18 years or older
- Admission to the Intensive Care Unit (ICU) of Ghent University Hospital
- Treatment with veno-venous extracorporeal membrane oxygenation (VV- ECMO)
- ICU admission between 1 January 2019 and 31 December 2023
Exclusion Criteria:
- Receipt of renal replacement therapy (RRT) prior to ICU admission
- Patients already receiving VV-ECMO at the time of admission to the ICU of Ghent University Hospital (i.e., patients referred from another hospital on VV-ECMO)
- Patients who received VV-ECMO immediately upon admission to the ICU of Ghent University Hospital
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Difference in urine output (staged by KDIGO criteria) 6h before and after start veno-venous ECMO and ultraprotective ventilation
Time Frame: 6 hours
|
The difference in urine output will be investigated before and after start of veno-venous ECMO together with the initiation of ultraprotective ventilation.
To compare the difference in urine output a timeframe of 6 hours before ECMO wil be compared to a timeframe six hours after ECMO initiation.
The 6 hour timeframe was choosen because this is the duration of the AKI KDIGO stage 1 urine output criterium.
|
6 hours
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Difference in urine output (staged by KDIGO criteria) 12h before and after start veno-venous ECMO and ultraprotective ventilation.
Time Frame: 12 hours
|
The difference in urine output will be investigated before and after start of veno-venous ECMO together with the initiation of ultraprotective ventilation.
To compare the difference in urine output a timeframe of 12 hours before ECMO will be compared to a 12 hour timeframe after ECMO initiation.
The 12 hour timeframe was choosen because this is the duration of the AKI KDIGO stage 2 urine output criterium.
|
12 hours
|
|
Difference in urine output (staged by KDIGO criteria) 24h before and after start veno-venous ECMO and ultraprotective ventilation.
Time Frame: 24 hours
|
The difference in urine output will be investigated before and after start of veno-venous ECMO together with the initiation of ultraprotective ventilation.
To compare the difference in urine output a timeframe of 24 hours before ECMO will be compared to a 24 hour timeframe after ECMO initiation.
The 24 hour timeframe was choosen because this is the duration of the AKI KDIGO stage 3 urine output criterium.
|
24 hours
|
|
Difference in serum creatinine (staged by KDIGO criteria) 24h before and after start veno-venous ECMO and ultraprotective ventilation.
Time Frame: 24 hours
|
The difference in serum creatinine will be investigated before and after start of veno-venous ECMO together with the initiation of ultraprotective ventilation.
To compare the difference in serum creatinine a timeframe of 24 hours before ECMO will be compared to a 24 hour timeframe after ECMO initiation.
Acute kidney injuri and it severity will be defined by the KDIGO definition and classification.
|
24 hours
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- ONZ-2025-0269
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.